viewTesla Inc

US judge approves Elon Musk's settlement with SEC over his Tesla go-private tweet

Resolving the case allows the electric-car maker to go back to the business of building vehicles

Tesla signage
Judge Alison Nathan signed off on the deal Tuesday, after Musk and the SEC said the agreement was in the best interest of investors

A US district court judge approved Tesla Inc (NASDAQ:TSLA) CEO Elon Musk's $40 million settlement with the Securities and Exchange Commission over fraud charges stemming from his early August tweet to take the company private, a report by Bloomberg said.

Judge Alison Nathan signed off on the deal Tuesday, after Musk and the SEC said the agreement was in the best interest of investors in the electric-car maker. The company will pay $20 million and Musk will also pay a $20 million penalty.

Musk had tweeted on August 7 that he planned to take the company private and that funding had been "secured," a claim that turned out to be not accurate and prompted some investors to sue him as a result.

The plan was eventually abandoned by Musk and the SEC swiftly opened an investigation. Within a few days of the settlement, Musk fired off another tweet insulting the SEC.

Despite muddling the picture, the deal went ahead. 

Resolution of the case would allow Tesla to move on from the issue and go back to the business of producing electric vehicles.

READ: Tesla starts off 4Q with strong production numbers; Musk tweets about climate change

As part of the settlement, Musk agreed to relinquish the post of chairman of Tesla although he remains CEO.

The market welcomed news the settlement had been finalized, with Tesla shares hitting a session top of $273.88 and trading 3.66% up at $269.08.

Reporting by Rene Pastor, contactable on [email protected]

Quick facts: Tesla Inc

Price: 359.52 USD

Market: NASDAQ
Market Cap: $64.8 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

10 hours, 39 minutes ago

2 min read